"It's speculative, but I think we could have a real opportunity here," said Cramer
NPS Pharmaceuticals CEO Dr. Francois Nader discusses the approval of its short bowel syndrome drug Gattex, and what's next for the company.
TheStreet.com offers up 13 biotech predictions for 2013.